Immunosuppressive therapies after heart transplantation: best, better, and beyond
- 1 March 2000
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 15 (2) , 108-114
- https://doi.org/10.1097/00001573-200003000-00008
Abstract
Despite the significant advances in transplantation immunology and immunosuppressive therapies over the past 30 years, current immunosuppressive regimens are still inadequate in the majority of cardiac transplant recipients. Although short-and long-term survival rates have improved significantly, only 50% will survive 10 years and very few will survive 20 years. Complications of overimmunosuppression and underimmunosuppression account for the majority of these deaths. Only true “immunologic” tolerance can provide the outcome we pursue, namely, prolonged allograft function and otherwise normal immune function without chronic immunosuppressive therapy and its risks. Until a successful tolerance-inducing protocol is developed, we must use the current and upcoming immunosuppressive agents and techniques.Keywords
This publication has 29 references indexed in Scilit:
- A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus11This study was sponsored by a grant from Fujisawa USA, Deerfield, Illinois.22The authors were working on behalf of the Tacrolimus US Heart Transplant Multicenter Study Group. Other members of the Study Group included (principal investigator listed first): UTAH Cardiac Transplant Program, Salt Lake City, Utah: David O. Taylor, MD, Dale G. Renlund, MD, Abdallah G. Kfoury, MD; St. Luke’s Episcopal Hospital/Texas Heart Institute, Houston, Texas: O. H. Frazier, MD, Branislav Radovancevic, MD, Edward K. Massin, MD; University of Wisconsin Hospitals and Clinics, Madison, Wisconsin: Robert M. Mentzer, Jr., MD, Charles C. Canver, MD, Robert B. Love, MD; Ochsner Medical Foundation, New Orleans, Louisiana: Frank W. Smart, MD, Hector O. Ventura, MD, Dwight D. Stapleton, MD, Mandeep Mehra, MD; University of Southern California, Los Angeles, California: Mark L. Barr, MD, Vaugh A. Starnes, MD; Medical College of Virginia, Richmond, Virginia: David E. Tolman, MD, Albert Guerraty, MD, David Salter, MD; Cleveland Clinic Foundation, Cleveland, Ohio: James B. Young, MD; Data Management and Statistical Coordinating Center-The EMMES Corporation, Potomac, Maryland: Paul VanVeldhuisen, MS, Anne Lindblad, PhD, Anita Yaffe, MSN, MPH.The Journal of Heart and Lung Transplantation, 1999
- SIROLIMUS (RAPAMYCIN)-BASED THERAPY IN HUMAN RENAL TRANSPLANTATIONTransplantation, 1999
- Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipientsThe Lancet, 1997
- Chimerism and tolerance: From freemartin cattle and neonatal mice to humansHuman Immunology, 1997
- Chimerism and transplantation tolerance: cause and effectImmunology Today, 1996
- The lost chord: microchimerism and allograft survivalImmunology Today, 1996
- MULTIPLE VECTORS EFFECTIVELY ACHIEVE GENE TRANSFER IN A MURINE CARDIAC TRANSPLANTATION MODEL IMMUNOSUPPRESSION WITH TGF-β OR vIL-10Transplantation, 1995
- Chronic myelogenous leukemia after lymphoid irradiation and heart transplantationThe Annals of Thoracic Surgery, 1994
- ‘Actively Acquired Tolerance’ of Foreign CellsNature, 1953
- Immunogenetic Consequences of Vascular Anastomoses Between Bovine TwinsScience, 1945